Methods treat neurological disorders, for example neurodegenerative disorders such as Alzheimers disease, Parkinsons disease and stroke. Particularly although not exclusively, GIP/GLP-1 co-agonist peptide is used in the treatment of such neurological disorders. Pharmaceutical compositions include a GIP/GLP-1 co-agonist peptide for use in treatment of such disorders.
